Skip to main content

Overview

Skip to main content

Overview

Current Location and Language

United States

Argentina

Australia

Austria

Belarus

- Belarusian - English

Belgium

- English - Nederlands - Français

Brazil

Bulgaria

- Български

Canada

- English - Français

China

- 中文 - English

Chile

Colombia

Croatia

Czech Republic

Denmark

- Dansk

Ecuador

Estonia

- Eesti - English

Finland

France

Germany

Greece

- ελληνικά

Hong Kong

- 繁體中文 - English

Hungary

India

Indonesia

Ireland

Israel

Italy

Japan

Korea

Latvia

- Latvian - English

Lithuania

- Lithuanian - English

Malaysia

Mexico

Netherlands

New Zealand

Norway

- Norsk

Pakistan

Peru

Philippines

Poland

Portugal

Russia

- Русский

Romania

Serbia

Saudi Arabia

- English - العربية

Singapore

Slovenia

Slovakia

South Africa

Spain

Sweden

Switzerland

- Deutsch - Français

Taiwan

Thailand

- ภาษาไทย

Tunisia

Turkey

- Türk

United Kingdom

United States

Ukraine

Vietnam

- Tiếng Việt - English

Venezuela

Event Details

Overview > Investor Relations > News & Events > Event Details

REVIEW OF PALBOCICLIB PHASE 2 PALOMA-1 RESULTS AT AACR ANNUAL MEETING 2014

04/06/2014 8:30 PM ET

Presentation (opens in new window)
Transcript (opens in new window)

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Pfizer, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Pfizer to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert Options

Investor Alert Options *

News

Quarterly Reports

Annual Reports

SEC Filings

End of Day Stock Quote

Events & Presentations

Email Alert Sign Up Confirmation

Investors
Careers
Media
Partners

Grant Seekers
Health Care Professionals
Business To Business
Merchandise

Privacy Statement
Terms Of Use
Contact Us

United States © Pfizer Inc. All rights reserved

Forward-Looking Statements of Pfizer Inc.

This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; manufacturing and product supply; our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitor; our expectations regarding the impact of COVID-19 on our business; plans for and prospects of our acquisitions, dispositions and other business-development activities, and our ability to successfully capitalize on these opportunities; and discussions relating to strategic reviews, capital allocation objectives, dividends and share repurchases, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the transcript speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Forward-Looking Statements of Pfizer Inc.

This webcast may contain forward-looking statements about, among other things, our anticipated operating and financial performance, reorganizations, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; our efforts to respond to COVID-19, including the Pfizer-BioNTech COVID-19 vaccine and our investigational protease inhibitor; and our expectations regarding the impact of COVID-19 on our business that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

A description of these risks and uncertainties can be found in Pfizer’s most recent Annual Report on Form 10-K and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in the transcript speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.